The Northwest Community Clinical Oncology Program has been in existence since 1983, and is now applying for competitive renewal. The CCOP consists of a total of 39 participating physicians, including oncologists and a variety of other specialists, and 11 hospital facilities located in Southwestern Washington and Northern Oregon. The CCOP utilizes four research bases, to include the Southwest Oncology Group, M.D. Anderson Cancer Center, University of Rochester Cancer Center, and the National Surgical Adjuvant Breast and Bowel Project. The objective of the CCOP is to provide continued clinical cancer research capabilities to its various communities through well-defined data management and quality assurance mechanisms. The CCOP will provide community physicians the opportunity of continued participation in a wide variety of clinical trials sponsored by these research bases, to include not only treatment but cancer prevention and control trials. Through this mechanism, the latest and most up-to-date cancer treatment regimens can be provided to patients. It is anticipated that further increase in accrual to clinical trials will be possible throughout the next five years. The funds obtained through a successful application will be used to support the administration of these activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035281-14
Application #
2429665
Study Section
Special Emphasis Panel (SRC (16))
Project Start
1983-09-15
Project End
1998-05-31
Budget Start
1997-06-01
Budget End
1998-05-31
Support Year
14
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Multicare Health System
Department
Type
DUNS #
City
Tacoma
State
WA
Country
United States
Zip Code
98405
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 109 publications